Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans

Inclusion Criteria: * 21-65 years of age * Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for alcohol use disorder, and alcohol is self-identified as primary substance of misuse. * Actively in treatment at VA Palo Alto HCS Addiction Treatment Service * Able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures. Exclusion Criteria: * History of Schizophrenia Spectrum Disorders, Bipolar Disorders, a * Current substance use disorder that exceeds the severity of the AUD (based on DSM-5 diagnostic criteria) * Current use of an FDA approved medication (i.e., disulfiram, acamprosate, and naltrexone) for treatment of AUD, * Active current suicidal intent or plan (patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial), * Any form of previous TMS or electroconvulsive treatment. * Thyroid disease, * Unstable congestive heart failure, angina, other severe cardiac illness as defined by treatment regimen changes in the prior 3 months * Cerebrovascular accident * Cancer if \< 1 year since end of treatment * Unstable diabetes * COPD requiring oxygen supplementation * Alzheimer's disease * Parkinson's disease * Any Biomedical implants with ferromagnetic content * Neurostimulation devices, cardiac pacemakers or any magnetic resonance contraindications * Traumatic brain injury with self-reported or observed loss of consciousness \> 30 minutes * Any primary or traumatically induced seizure disorder * Lack of fluency in English, Wechsler Adult Reading Test below the 7th percentile (i.e., moderate or greater impairment in estimated general intelligence), * Females who are pregnant or actively attempting pregnancy (conservative exclusion for magnetic resonance research), * Current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for TMS treatment.